CorMedix (CRMD) Expected to Announce Quarterly Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is projected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $27.46 million for the quarter.

CorMedix Stock Up 12.9 %

NASDAQ:CRMD opened at $10.71 on Friday. The company has a fifty day simple moving average of $10.54 and a two-hundred day simple moving average of $9.51. The company has a market cap of $649.85 million, a price-to-earnings ratio of -13.22 and a beta of 1.53. CorMedix has a 52 week low of $3.03 and a 52 week high of $13.85.

Analysts Set New Price Targets

Several equities analysts have commented on CRMD shares. Leerink Partners started coverage on shares of CorMedix in a research note on Friday. They issued an “outperform” rating and a $18.00 price target for the company. Leerink Partnrs upgraded shares of CorMedix to a “strong-buy” rating in a research note on Friday. Royal Bank of Canada boosted their target price on shares of CorMedix from $11.00 to $12.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of CorMedix in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.